PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Therapy Focus: Cystic Fibrosis
From issue 61 of the PharmaDeals Review (2005-07-01)
Cystic fibrosis (CF) is a chronic and progressive genetic disease of the mucus glands, which primarily affects the lungs and digestive system. While disease management strategies have improved the quality of life of CF patients, and also have significantly increased their life spans, there is still an overwhelming need for therapies that go further towards a cure for this fatal disease.
Available as PDF
(Subscribers only)
Novartis Chooses the UK for High-Value COPD Alliance
From issue 60 of the PharmaDeals Review (2005-06-01)
The UK biotech industry unanimously applauded British biotechnology companies Arakis and Vectura Group when they signed the fourth largest European licensing deal with Swiss pharmaceutical company Novartis. What promise does AD 237 hold, however, and how well will Novartis compete against key players in the chronic obstructive pulmonary disease field?
Available as PDF
(Subscribers only)
Dividing Opinion: Shire's Move to Purchase TKT
From issue 60 of the PharmaDeals Review (2005-06-01)
Shire Pharmaceutical Group's decision to buy the loss-making US biotech Transkaryotic Therapies (TKT) for US$1.57 B has split the opinion of analysts and investors alike. Although there are a number of positives to be gained from such a move, various criticisms have been voiced, particularly at the size of the purchase price. What is more, it remains to be seen whether the acquisition will actually materialise.
Available as PDF
(Subscribers only)
Generics Companies: Moving Up the Food Chain
From issue 60 of the PharmaDeals Review (2005-06-01)
Dr David Cavalla of Arachnova offers a personal perspective. He considers the current drivers in generics pharmaceutical companies, their future strategies and the impact that this has on the opportunities for these companies as licensing partners.
Available as PDF
(Subscribers only)
Therapy Focus: Cancer Vaccines
From issue 60 of the PharmaDeals Review (2005-06-01)
Cancer is an area of significant unmet need in which targeted therapies such as vaccines could offer significant benefits over traditional treatments. This feature investigates the current approaches to cancer vaccine development and examines some of the major deals in the field from recent years.
Last Issue PDF
RSS